Skip to content
info@ibsgranada.es
FacebookTwitterLinkedInInstagramYouTube
ibs logo.GRANADA
  • ibs.GRANADA
  • The Institute
    • The Institute
    • Organizational structure
    • Management Units
    • Economic information
    • Rehab
    • Responsible Research and Innovation (RRI)
    • Researcher Area
    • Annual Reports ibs.GRANADA
    • Webmail access
    • Transparency
  • Research
    • Own Plan ibs.GRANADA
    • Research Areas
    • Research groups
    • Clinical research
    • Collaboration network between groups of the ibs.GRANADA
    • Researcher Finder
    • Publications Search
  • Innovation
    • Innovation
    • Technology Offers
    • Clinical practice guidelines
  • international
    • International Projects Unit
    • International Projects
    • International Networks
  • Training
    • Training
    • Research Sessions
    • Conferences and Courses
    • Mentoring Program ibs.GRANADA
    • PhD Programs
    • Official University Master's Degrees
  • News
    • Calls for applications
    • News
    • Events
  • Job vacancies
    • Job vacancies
    • Human Resources Strategy for Researchers of the European Commission (HRS4R)
  • Digital Platforms

Phase IIb clinical study evaluating the efficacy and safety of TAR-200 in combination with Cetrelimab, TAR-200 alone, or Cetrelimab alone in participants with high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calm

CLINICAL TRIAL WITH MEDICINES

Home · A06-Clinical Oncology and Liquid Biopsy

Clinical trial information

  • Promoter: JANSSEN-CILAG, SA
  • Phase: II
  • Execution start: 10/03/2023
  • End of execution: 30/03/2027
  • IP: IGNACIO PUCHE SANZ
facebook icon twitter icon LinkedIn icon whatsapp icon

Post navigation

Phase II clinical study of Durvalumab (MEDI4736) plus Tremalimumab for the treatment of patients with advanced neuroendocrine tumors of gastroenteropathic or pulmonary origin (DUNE)
Phase III, multicenter, double-blind, placebo-controlled clinical study comparing chemoimmunotherapy paclitaxel-carboplatin-oregovomab) versus chemotherapy (paclitaxel-carboplatin-placebo) in patients with epithelial carcinoma of the ovary

ibs.Granada logo

  • info@ibsgranada.es
  • Avda. De Madrid, 15
    External Consultation Pavilion, 2nd Floor
    18012 Grenada.
  • facebook icon
  • twitter icon
  • instagram icon
  • linkedin icon
  • youtube icon
University of Granada
Investigate +
© 2026 ibs.GRENADA
  • Legal Notice
  • Cookies Policy
  • Privacy Policy
  • Contact
  • Site map

This website, managed by FIBAO, uses its own and third-party cookies to obtain statistical data and create browsing profiles. More information in our Cookies policy.

X
ibs logo.GRANADA
Powered by  GDPR Cookie Compliance
Privacy summary

This website uses cookies so that we can offer you the best possible user experience. The information of the cookies is stored in your browser and performs functions such as recognizing you when you return to our website or helping our team understand which sections of the website you find most interesting and useful.

Technical and necessary cookies

The strictly necessary cookies must always be activated so that we can save your cookie settings preferences.

Analytics and optimization

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, or the most popular pages.

Leaving this cookie active allows us to improve our website.

Cookie policy

More information about our Cookies policy